Last reviewed · How we verify
Topical travoprost
At a glance
| Generic name | Topical travoprost |
|---|---|
| Also known as | travoprost |
| Sponsor | Glaukos Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- PSLT Compared to Prostaglandin Analogue Eye Drops (NA)
- Interval Intraocular Pressure in Intravitreal Injection Study (NA)
- Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo (PHASE4)
- How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used? (PHASE4)
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (PHASE4)
- Trabeculectomy Versus 2-iStent and Prostaglandin Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical travoprost CI brief — competitive landscape report
- Topical travoprost updates RSS · CI watch RSS
- Glaukos Corporation portfolio CI